Exopharm
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Industry Lists
Public Companies - non WAExopharm Limited (EX1) is a clinical-stage Australian exosome medicine company developing naive exosome products for regenerative medicine and engineered exosomes for new precision medicines. Exopharm owns a purification technology called Ligand-based Exosome Affinity Purification (LEAP).
Lists and Charts
Share Price
Closing price for the last 90 trading days
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 893rd |  | Exopharm | $3.4m |
| 1051st | | Kaili Resources | $425k |
| 1052nd | | CD Private Equity Fund I | $422k |
| 1055th | | Native Mineral Resources Holdings | $408k |
| 1056th | | Imperial Pacific | $395k |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 548th | CD Private Equity Fund I | 8% | 14% |
| 918th | Imperial Pacific | -13% | 7% |
| 1052nd | Exopharm | -22% | -52% |
| 1066th | Kaili Resources | -23% | -23% |
| 1651st | Native Mineral Resources Holdings | -63% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Company Activity
| NEW ROLE: Clarke Barlow, Non-Executive Director | 17 Nov 2023 |
| RANKING: 918 Down from 701 in Public Companies - non WA list | 02 Oct 2023 |
| ECM DEAL: New deal has been added | 29 Sep 2023 |
| NEW ROLE: David Oxley, | 03 Nov 2022 |
| NEW ROLE: Michael West, | 03 Nov 2022 |
| NEW ROLE: Gregor Lichtfuss, | 02 Sep 2022 |
| NEW ROLE: Christopher Baldwin, | 02 Sep 2022 |
| NEW ROLE: David Franks, Company Secretary | 07 Apr 2022 |
